

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8064450

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UGUR SAHIN	12/06/2013
ÖLZEM TÜRECI	12/16/2013
MICHAEL KOSLOWSKI	12/10/2013
KORDEN WALTER	12/16/2013
STEFAN WÖLL	12/16/2013
BERND HUBNER	12/10/2013
MICHAEL ERDELJAN	12/16/2013
MICHAEL WEICHEL	12/10/2013
MARIA KREUZBERG	12/16/2013
RECEIVING PARTY DATA	
Name:	GANYMED PHARMACEUTICALS AG
Street Address:	FREILIGRATHSTRASSE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
Name:	JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Street Address:	SAARSTRASSE 21
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55122
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17138403
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3122698000
Email:	koleary@nge.com, ipusmail@nge.com

Correspondent Name: NEAL, GERBER & EISENBERG LLP
Address Line 1: TWO NORTH LASALLE STREET
Address Line 2: SUITE 1700
Address Line 4: CHICAGO, ILLINOIS 60602

ATTORNEY DOCKET NUMBER: 026156-8031

NAME OF SUBMITTER: KEVIN A. O'CONNOR

SIGNATURE: /Kevin A. O'Connor/

DATE SIGNED: 07/18/2023

Total Attachments: 25

source=026156-8031 Assignment - Inv#page3.tif
source=026156-8031 Assignment - Inv#page4.tif
source=026156-8031 Assignment - Inv#page5.tif
source=026156-8031 Assignment - Inv#page6.tif
source=026156-8031 Assignment - Inv#page7.tif
source=026156-8031 Assignment - Inv#page8.tif
source=026156-8031 Assignment - Inv#page9.tif
source=026156-8031 Assignment - Inv#page10.tif
source=026156-8031 Assignment - Inv#page11.tif
source=026156-8031 Assignment - Inv#page12.tif
source=026156-8031 Assignment - Inv#page13.tif
source=026156-8031 Assignment - Inv#page14.tif
source=026156-8031 Assignment - Inv#page15.tif
source=026156-8031 Assignment - Inv#page16.tif
source=026156-8031 Assignment - Inv#page17.tif
source=026156-8031 Assignment - Inv#page18.tif
source=026156-8031 Assignment - Inv#page19.tif
source=026156-8031 Assignment - Inv#page20.tif
source=026156-8031 Assignment - Inv#page21.tif
source=026156-8031 Assignment - Inv#page22.tif
source=026156-8031 Assignment - Inv#page23.tif
source=026156-8031 Assignment - Inv#page24.tif
source=026156-8031 Assignment - Inv#page25.tif
source=026156-8031 Assignment - Inv#page26.tif
source=026156-8031 Assignment - Inv#page27.tif

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, and Michael Weichel (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 27536US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on November 12, 2013, in the United States Patent and Trademark Office as Serial No. 14/117,118 (the "'118 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '118 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '118 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.


By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this 6 day of 12, 2013.



Ugur Sahin

WITNESSED by Silke Fuchs this 6 day of Dec, 2013.

EXECUTED this _____ day of _____, 2013.

Özlem Türeci

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Korden Walter

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Stefan Wöll

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Maria Kreuzberg

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Bernd Hubner

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Erdeljan

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Weichel

WITNESSED by _____ this _____ day of _____, 2013.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, and Michael Weichel (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 27536US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on November 12, 2013, in the United States Patent and Trademark Office as Serial No. 14/117,118 (the "'118 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '118 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '118 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2013.

Ugur Sahin


WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Özlem Türeci

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 10 day of Dec, 2013.



Michael Koslowski

WITNESSED by  this 10 day of Dec, 2013.

EXECUTED this _____ day of _____, 2013.

Korden Walter

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Stefan Wöll

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Maria Kreuzberg

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Bernd Hubner

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Erdeljan

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Weichel

WITNESSED by _____ this _____ day of _____, 2013.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, and Michael Weichel (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 27536US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on November 12, 2013, in the United States Patent and Trademark Office as Serial No. 14/117,118 (the "'118 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '118 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '118 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2013.

Ugur Sahin

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Özlem Türeçli

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Korden Walter

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Stefan Wöll

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Maria Kreuzberg

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 10 day of DEC, 2013.

Bernd Hubner

Bernd Hubner

WITNESSED by Silke Renter this 10 day of DEC, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Erdeljan

WITNESSED by _____ this _____ day of _____, 2013.

CASE NO. 27536US01

EXECUTED this _____ day of _____, 2013.

Michael Weichel

WITNESSED by _____ this _____ day of _____, 2013.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, and Michael Weichel (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 27536US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on November 12, 2013, in the United States Patent and Trademark Office as Serial No. 14/117,118 (the "'118 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '118 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '118 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2013.

Ugur Sahin

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Özlem Türeçli

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Korden Walter

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Stefan Wöll

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Maria Kreuzberg

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Bernd Hubner

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Erdeljan

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 09 day of Dec., 2013.

Michael Weichel
Michael Weichel

WITNESSED by Silke Linker this 10 day of Dec., 2013.

PATENT ASSIGNMENT

WHEREAS, we, Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, and Michael Weichel (collectively the "the Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "ANTIBODIES FOR TREATMENT OF CANCER" and identified as Case No. 27536US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed on November 12, 2013, in the United States Patent and Trademark Office as Serial No. 14/117,118 (the "'118 Application").

WHEREAS, Ganymed Pharmaceuticals AG, a German corporation having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, together with Johannes Gutenberg-Universität Mainz, having a place of business at Saarstrasse 21, Mainz, Germany 55122, (collectively "the Assignees") is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignees, their successors and assigns, the entire right, title and interest in and to said application and the inventions and improvements disclosed therein, and in any and all other United States (provisional or non-provisional) applications based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignees to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the names of the Assignees or otherwise as said Assignees may deem advisable, under the International Convention or otherwise. The Assignors further acknowledge the assignment of all domestic and foreign intellectual property rights to the Assignee(s) related to the '118 Application. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent stemming from the '118 Application to said Assignees.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignees, their successors and assigns, to execute any and all continuation,

continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, that said Assignees, their successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignees, their successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignees, their successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignees, their successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

By way of an Addendum to Patent Assignments, which was executed on May 19, 2010 and June 2, 2010, Ganymed Pharmaceuticals AG ("Ganymed") and Johannes Gutenberg-Universität Mainz ("Universität Mainz") have acknowledged that, as to the relationship between the Ganymed and Universität Mainz, the terms of this Assignment shall be subject to the terms of the Cooperation Treaties entered into between Universität Mainz and Ganymed dated June 28, 2005 and December 30, 2008, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Treaty dated December 30, 2008. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of this Assignment, the terms of the Cooperation Treaties shall supersede and govern.

This Assignment shall be binding upon and shall inure to the benefit of the Assignees and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.


[SIGNATURE PAGES FOLLOW]

EXECUTED this _____ day of _____, 2013.

Ugur Sahin

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 16 day of Dec, 2013.



Ozlem Tureci

WITNESSED by Silke Renk this 16 day of Dec, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Koslowski

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 16 day of Dec, 2013.



Korden Walter


WITNESSED by Silke Renk this 16 day of Dec, 2013.

EXECUTED this 16 day of Dec, 2013.


Stefan Wöll

WITNESSED by Silke Renter this 16 day of Dec, 2013.

EXECUTED this 16 day of Dec, 2013.


Maria Kreuzberg

WITNESSED by Silke Renter this 16 day of Dec, 2013.

EXECUTED this _____ day of _____, 2013.

Bernd Hubner

WITNESSED by _____ this _____ day of _____, 2013.

EXECUTED this 16 day of Dec, 2013.


Michael Erdeljan

WITNESSED by Silke Renter this 16 day of Dec, 2013.

EXECUTED this _____ day of _____, 2013.

Michael Weichel

WITNESSED by _____ this _____ day of _____, 2013.